Posts

Posted on

UWMC Securities Losses: UWM Holdings Investors with Losses on their Investment are Reminded to Contact BFA Law by October 13 Deadline in Securities Fraud Class Action

UWM has been sued for securities fraud after its stock plummeted 34.78% because UWM allegedly misrepresented its mortgage servicing rights hedging strategy and the risks created by hedging connected to the Two Harbors transaction

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against UWM Holdings Corporation (NYSE:UWMC) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in UWM, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/uwm-holdings-class-action-lawsuit.

Key Details of the UWM ($UWMC) Class Action:

  • Lead Plaintiff Deadline: October 13, 2026
  • Alleged Misconduct: Securities fraud alleging that UWM misrepresented its mortgage servicing rights hedging strategy and the risks created by hedging connected to the Two Harbors transaction
  • Stock Drop: August 6, 2026 – 34.78% Stock Drop
  • Court: U.S. District Court for the Eastern District of Michigan
  • Action: Contact BFA Law to discuss your rights

Investors have until October 13, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in UWM securities. The class action is pending in the U.S. District Court for the Eastern District of Michigan. It is captioned Bond v. UWM Holdings Corporation et al., No. 26-cv-12862.

Why is UWM Being Sued for Securities Fraud?

UWM originates, sells, and services residential mortgage loans in the United States. In December 2025, UWM and Two Harbors Investment Corp., owner of RoundPoint Mortgage Servicing, signed an all-stock merger agreement valued at $1.3 billion.

According to the complaint, in March 2026, Two Harbors terminated the UWM agreement after CrossCountry Mortgage made a competing cash offer and agreed to pay UWM’s termination fee.

As alleged, UWM failed to disclose that it had deviated from its traditional strategy of not hedging its mortgage servicing rights by taking a major hedge position, that it over-hedged itself in anticipation of the Two Harbors transaction, and that its purported efforts to balance risk created excess hedging risk.

Why did UWM’s Stock Drop?

On August 5, 2026, after the market closed, UWM reported Q2 2026 financial results, including a $603.2 million interest rate derivatives loss which contributed to a $451.9 million second-quarter net loss. Total equity also fell 43.6% year over year, reflecting the net loss and derivative-related charges.

Then, on August 6, 2026, UWM disclosed that it “over-hedged” while protecting against the Two Harbors transaction and stated that UWM does not traditionally hedge its mortgage servicing rights. UWM further disclosed that when it was acquiring Two Harbors and a large mortgage servicing rights book, “it created a little more risk,” that UWM “did put a hedge on to protect against that risk,” and that “the Two Harbors transaction went away,” creating a hedge loss. On this news, UWM’s stock dropped $0.64 per share, or 34.78%, from a closing price of $1.84 per share on August 5, 2026, to $1.20 per share on August 6, 2026.

Click here for more information:

https://www.bfalaw.com/cases/uwm-holdings-class-action-lawsuit

.

What Can You Do?

If you invested in UWM, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/uwm-holdings-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/uwm-holdings-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

GDDY Securities Losses: GoDaddy Investors with Losses on their Investment are Reminded to Contact BFA Law by October 26 Deadline in Securities Fraud Class Action

GoDaddy has been sued for securities fraud after its stock plummeted 14.28% because GoDaddy allegedly misrepresented its customer acquisition and go-to-market strategy

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GoDaddy Inc. (NYSE:GDDY) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in GoDaddy, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/godaddy-class-action-lawsuit.

Key Details of the GoDaddy ($GDDY) Class Action:

  • Lead Plaintiff Deadline: October 26, 2026
  • Alleged Misconduct: Securities fraud alleging GoDaddy misrepresented its customer acquisition and go-to-market strategy
  • Stock Drop: February 25, 2026 – 14.28% Stock Drop
  • Court: U.S. District Court for the Southern District of New York
  • Action: Contact BFA Law to discuss your rights

Investors have until October 26, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in GoDaddy common stock. The class action is pending in the U.S. District Court for the Southern District of New York. It is captioned Johnson v. GoDaddy Inc. et al., No. 26-cv-7144.

Why is GoDaddy Being Sued for Securities Fraud?

GoDaddy is an internet domain registry, domain registrar, and web hosting company that primarily serves small businesses, entrepreneurs, and other customers seeking tools to build and manage an online presence.

According to the complaint, GoDaddy repeatedly told investors that its strategy was focused on attracting “high-intent” customers who were likely to buy more products and spend more money, while allegedly failing to disclose that it had introduced a heavily discounted $4.99 promotional offer for one-year dotcom domain contracts.

As alleged, the promotion contradicted GoDaddy’s public messaging that it had turned off front-end discounting and was not pursuing customer growth for its own sake. The complaint alleges that the promotion encouraged shorter-term, lower-value contracts, reduced upfront bookings, and rendered GoDaddy’s statements about demand, average order size, and bookings growth misleading.

Why did GoDaddy’s Stock Drop?

On February 24, 2026, after the market closed, GoDaddy disclosed that total bookings growth sharply decelerated to 5% in Q4 2025, down from 9% the prior quarter and below analyst expectations. GoDaddy also disclosed that it had expanded its go-to-market approach and introduced a promotional price for dotcom domains with a one-year term. The Company stated that the offer increased new customer volume but that the shift in term mix and promotional pricing reduced upfront bookings and near-term revenue.

On this news, GoDaddy’s stock dropped $13.18 per share, or 14.28%, from a closing price of $92.30 per share on February 24, 2026, to $79.12 per share on February 25, 2026.

Click here for more information:

https://www.bfalaw.com/cases/godaddy-class-action-lawsuit

.

What Can You Do?

If you invested in GoDaddy, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/godaddy-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/godaddy-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

LULU Securities Losses: Lululemon Investors with Losses on their Investment are Reminded to Contact BFA Law about the Ongoing Securities Fraud Investigation

BFA Law is investigating whether Lululemon committed securities fraud by making false and misleading statements to investors regarding the strength of its growth and overall business health.

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into lululemon athletica inc. (NASDAQ:LULU) for potential securities fraud after significant stock drops.

If you invested in Lululemon, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/lululemon-class-action-lawsuit.

Key Details of the Lululemon ($LULU) Class Action Investigation:

  • Investigation Overview: Securities fraud investigation relating to Lululemon’s misrepresentations about the strength of its growth and overall business health
  • Largest Stock Drop: September 4, 2026 – 17.4% Stock Drop
  • Action: Contact BFA Law to discuss your rights

Why is Lululemon Being Investigated for Securities Fraud?

Lululemon is being investigated for securities fraud following significant stock drops. The decline in Lululemon’s stock price caused significant losses to investors.

Lululemon is a designer, distributor, and retailer of technical athletic apparel, footwear, and accessories. Lululemon’s apparel includes pants, shorts, tops, and jackets designed for athletic activities, as well as fitness-oriented apparel and accessories.

BFA is investigating whether Lululemon misled investors about the strength of its growth and overall business health.

Why did Lululemon’s Stock Drop?

On April 22, 2026, after market close, Lululemon announced that Heidi O’Neill would be appointed as CEO effective September 8, 2026. Analysts expressed skepticism that O’Neill was well-suited for this role given her background.

On this news, the price of Lululemon stock declined by $21.79 per share, or 13.3%, from a closing price of $163.45 per share on April 22, 2026, to a closing price of $141.66 per share on April 23, 2026.

Then, on June 4, 2026, after market close, Lululemon disclosed that gross margins were down 4% year-over-year. Further, sales trends slowed at the end of the quarter due to both negative media commentary about Lululemon’s products and underwhelming results from new product launches.

On this news, the price of Lululemon stock declined by $10.96 per share, or 8.6%, from a closing price of $124.92 per share on June 4, 2026 to a closing price of $114.23 per share on June 5, 2026.

Then, on September 3, 2026, after market close, Lululemon announced a year-over-year revenue decline of 4.3%, including a 10% decline in same-store sales a 20% decline in Lululemon’s core products—leggings and women’s tops—during the quarter. Management lowered FY26 revenue, operating margins, EPS guidance, and issued fiscal 3Q26 EPS guidance which was 60% below analysts’ expectations.

On this news, the price of Lululemon stock declined by $21.16 per share, or 17.4%, from a closing price of $121.77 per share on September 3, 2026 to a closing price of $100.61 per share on September 4, 2026.

Click here for more information:

https://www.bfalaw.com/cases/lululemon-class-action-lawsuit

.

What Can You Do?

If you invested in Lululemon, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you.   Shareholders are not responsible for any court costs or expenses of litigation.   The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/lululemon-class-action-lawsuit

Or contact:

Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.”  One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/lululemon-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

RXT Securities Losses: Rackspace Technology Investors with Losses on their Investment are Reminded to Contact BFA Law by September 28 Deadline in Securities Fraud Class Action

A securities fraud class action lawsuit has been filed on behalf of Rackspace investors after its stock plummeted 33.6% because Rackspace allegedly misled investors about its AI efforts and their impact on the company’s financial performance.

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Rackspace Technology, Inc. (NASDAQ:RXT) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Rackspace, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/rackspace-class-action-lawsuit.

Key Details of the Rackspace ($RXT) Class Action:

  • Lead Plaintiff Deadline: September 28, 2026
  • Alleged Misconduct: Securities fraud alleging that Rackspace misled investors about its AI efforts and their impact on the company’s financial performance
  • Stock Drop: July 9, 2026 – 33.6% Stock Drop
  • Court: U.S. District Court for the Southern District of New York
  • Action: Contact BFA Law to discuss your rights

Investors have until September 28, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Rackspace securities. The class action is pending in the U.S. District Court for the Southern District of New York. It is captioned Morgan-Reed v. Rackspace Technology, Inc., No. 26-cv-6491.

Why is Rackspace Being Sued for Securities Fraud?

Rackspace is a hybrid cloud and AI solutions company that operates physical infrastructure to host cloud services and artificial intelligence. The company also provides Rackspace AI, a portfolio of AI services to help organizations scale AI adoption.

During the relevant period, the company announced it signed a memorandum of understanding with Advanced Micro Devices, Inc. (“AMD”) to assist in building out its AI infrastructure and enhance its AI capabilities. That same day, the company reaffirmed its full year revenue guidance.

Rackspace told investors that the “AMD piece really fits into how” the company’s technology stack operates. Rackspace also stated that the AMD partnership “give[s] [the Company] confidence in the full year Private Cloud growth profile.”

As alleged, in truth, the company’s AI efforts would require Rackspace to significantly re-prioritize its capacity and pull capacity away from revenue generating segments.

Why did Rackspace’s Stock Drop?

On July 9, 2026, Rackspace revealed that its AI investments would require a significant re-prioritization of resources and a “transition away” from certain revenue generating segments. As a result, Rackspace revealed it was cutting its full year 2026 revenue guidance by $150 million and its full year Private Cloud revenue outlook by $25 million.

This news caused the price of Rackspace stock to decline $2.21 per share, or 33.6%, from a closing price of $6.58 per share on July 8, 2026, to $4.37 per share on July 9, 2026.

Click here for more information:

https://www.bfalaw.com/cases/rackspace-class-action-lawsuit

.

What Can You Do?

If you invested in Rackspace, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/rackspace-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/rackspace-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

BBNX Securities Losses: Beta Bionics Investors with Losses on their Investment are Reminded to Contact BFA Law by November 3 Deadline in Securities Fraud Class Action

A securities fraud class action lawsuit has been filed on behalf of Beta Bionics investors after its stock plummeted over 37% because Beta Bionics allegedly misled investors about the safety, efficacy, and commercial success of its iLet medical device, potentially violating the federal securities laws

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Beta Bionics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit.

Key Details of the Beta Bionics ($BBNX) Class Action:

  • Lead Plaintiff Deadline: November 3, 2026
  • Alleged Misconduct: Securities fraud alleging that Beta Bionics misled investors about the safety of its iLet medical device
  • Largest Alleged Stock Drop: January 8–9, 2026 – 37% Stock Drop
  • Court: U.S. District Court for the Central District of California
  • Action: Contact BFA Law to discuss your rights

Investors have until November 3, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Beta Bionics common stock. The class action is pending in the U.S. District Court for the Central District of California. It is captioned Holtzman v. Beta Bionics, Inc., No. 26-cv-9999.

Why is Beta Bionics Being Sued for Securities Fraud?

Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (“iLet”), launched in 2023. The iLet is an insulin delivery system for treatment of diabetes types 1 and 2 that purports to be fully autonomous, determining 100% of insulin doses without manual carbohydrate counting or correction calculations by the user.

The complaint alleges that Beta Bionics falsely touted “the superior clinical outcomes of the iLet” and that healthcare professionals “are seeing good results from their patients and becoming more comfortable prescribing the iLet.”

However, the complaint alleges that in June 2025, the FDA issued Beta Bionics a Form 483 detailing more than 18,000 unreported complaints from iLet users since its launch. The complaints concerned, allegedly, cases of life-threatening hypoglycemia due to iLet’s aggressive insulin dosing algorithm which Beta Biotics failed to investigate or take corrective actions to address.

Why did Beta Bionics’ Stock Drop?

On January 8, 2026, after hours, Beta Bionics announced that a key business metric—the number of new patients starting iLet treatment, or “new patient starts”—had missed analyst estimates by nearly 10%. As alleged, this news caused the price of Beta Bionics stock to decline by $11.85 per share, or 37%, from a closing price of $31.99 per share on January 8, 2026 to a closing price of $20.14 per share on January 9, 2026.

Then, on February 24, 2026, the FDA publicly released a 10-page warning letter, which it had previously sent to Beta Bionics, stating that the Company failed to report instances of hypoglycemia caused by iLet malfunctions. As alleged, this news caused the price of Beta Bionics stock to decline by $0.66, or 4.9%, from a closing price of $13.55 per share on February 24, 2026 to a closing price of $12.89 per share on February 25, 2026.

Click here for more information:

https://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit

What Can You Do?

If you invested in Beta Bionics, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

CAPR Securities Losses: Capricor Therapeutics Investors with Losses on their Investment are Reminded to Contact BFA Law by September 28 Deadline in Securities Fraud Class Action

Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop.

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ:CAPR) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Capricor Therapeutics securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/capricor-class-action-lawsuit.

Key Details of the Capricor Therapeutics ($CAPR) Class Action:

  • Lead Plaintiff Deadline: September 28, 2026
  • Lawsuit Allegations: Securities fraud alleging Capricor made false statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License Application.
  • Largest Alleged Stock Drop: July 27, 2026 – 64.5% Stock Drop
  • Court: U.S. District Court for the Southern District of California
  • Action: Contact BFA Law to discuss your rights

Investors have until September 28, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Capricor securities. The class action is pending in the U.S. District Court for the Southern District of California. It is captioned Nkamga v. Capricor Therapeutics, Inc. et al., No. 26-cv-04385.

Why is Capricor Being Sued for Securities Fraud?

Capricor is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel, is an investigational cell therapy being developed for Duchenne muscular dystrophy.

According to the complaint, Capricor submitted a Biologics License Application to the FDA for Deramiocel in late 2024. In July 2025, the FDA issued a Complete Response Letter stating that the application did not meet the statutory requirement for substantial evidence of effectiveness and that additional clinical data was needed.

As alleged, Capricor failed to disclose that it adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel and that the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel BLA.

Why did Capricor’s Stock Drop?

On July 27, 2026, the FDA released briefing documents ahead of an advisory committee meeting concerning Deramiocel. The FDA briefing documents reportedly raised concerns about post-hoc changes to Capricor’s statistical analysis plan, including changes to the methodology for calculating the primary endpoint, PUL 2.0, shortly before the database was unlocked and unblinded. This news caused the price of Capricor stock to decline $12.70 per share, or 64.5%, from a closing price of $19.70 per share on July 24, 2026, to $7.00 per share on July 27, 2026, the following trading day.

On July 29, 2026, the FDA advisory committee met to discuss the Deramiocel BLA. The next day, a medical news website named Medscape reported that in a non-binding 9-3 vote, the panel concluded that available evidence did not support the efficacy of Deramiocel for treating DMD-associated cardiomyopathy. On this news, Capricor’s stock dropped $2.38 per share, or 36%, from a closing price of $6.57 per share on July 29, 2026, to $4.19 per share on July 30, 2026.

Click here for more information:

https://www.bfalaw.com/cases/capricor-class-action-lawsuit

.

What Can You Do?

If you invested in Capricor Therapeutics securities, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/capricor-class-action-lawsuit

Or contact:

Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/capricor-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 18, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a partnership with QIMA Life Sciences, a world leading preclinical dermatology CRO, to explore the potential of several of CDT’s assets in autoimmune skin diseases.

CDT plans to leverage QIMA’s unique access to human skin from both healthy donors and patients. The use of patient tissue offers the most clinically relevant data possible, providing rapid translation to clinic and providing potential license partners the highest level of confidence possible for clinical success.

Initial studies will be centred around tapinarof (VTAMA®), a drug currently approved for plaque psoriasis and atopic dermatitis in the US and Japan. CDT has created a robust intellectual property portfolio around tapinarof, including solid form and method-of-use patents in combination with other known drugs. QIMA will explore the potential of these novel combinations in psoriatic patient skin, with the aim of working towards a second generation tapinarof product with increased efficacy and patient benefits. VTAMA® is currently the number one branded topical treatment in the US, and CDT believe that developing a combination therapy could both expand, and extend, its market to further patient groups.

CDT also plans to investigate the potential of its proprietary tapinarof combinations in vitiligo, an autoimmune disease often associated with significant emotional and psychological distress for sufferers. Vitiligo is a common chronic autoimmune disorder affecting approximately 0.5%–2.0% of the global population, representing tens of millions of patients worldwide1. The global vitiligo drug market was estimated at approximately US$2.6 billion in 2025 and is projected to reach US$6.6 billion by 20302. Current approved treatments often prove intolerable for many patients, especially pediatric patients, and re-pigmentation can take a considerable amount of time, demonstrating a significant unmet need for new therapies that are effective, yet tolerable. Working with human skin will allow CDT to explore the potential of these combinations in the most physiologically relevant setting possible.

For further information or to discuss potential partnership opportunities, please contact the Company at [email protected].

About QIMA Life Sciences

QIMA Life Sciences is a contract research organization specializing in cellular and molecular pharmacology. It partners with pharmaceutical and biotechnology companies to advance research and accelerate drug development through tailored, science-driven solutions spanning early discovery through clinical development. By combining preclinical and clinical research and testing solutions with advanced AI-driven image analysis and digital data platforms, QIMA Life Sciences enables companies to generate the robust scientific evidence needed to bring innovative drugs to patients with confidence. www.qima-lifesciences.com

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors

CDT Equity Inc.
[email protected]

__________________________
1https://onlinelibrary.wiley.com/doi/full/10.1002/ski2.317
2https://www1.hkexnews.hk/app/sehk/2026/108643/documents/sehk26061501863.pdf



Posted on

Bimergen Energy Opens New Federal Market Channel for Energy Storage

These Relevant Opportunities Are Valued in the Hundreds of Millions of Dollars

Newport Beach, CA, Sept. 18, 2026 (GLOBE NEWSWIRE) — Bimergen Energy Corporation (NYSE American: BESS), a developer, owner, and operator of utility-scale and distributed battery energy storage systems, today announced that its wholly owned subsidiary, Emergen Energy, LLC, has completed its System for Award Management (SAM.gov) registration and received its Commercial and Government Entity (CAGE) code 23R51. Emergen’s registration is active for “All Awards,” establishing the registration foundation to compete for federal contracts and pursue eligible federal assistance opportunities, subject to individual solicitation and program requirements.

The milestone supports Bimergen’s strategy of expanding the commercial reach of its energy storage development capabilities and building relationships that advance energy infrastructure projects. With an active federal registration, Emergen is positioned to pursue opportunities with government agencies and explore collaboration with prime contractors and other industry partners.

Assigned by the Defense Logistics Agency, the CAGE code identifies Emergen within federal procurement systems. The combination of active SAM.gov registration and CAGE code assignment completes a foundational step in the Company’s preparation to participate in the federal marketplace.

“Completing our federal registration is a meaningful step in expanding the opportunities available to Bimergen,” said Cole Johnson, Co-CEO of Bimergen Energy. “Our focus is on developing energy storage infrastructure that strengthens grid reliability and delivers flexible power when needed. We now have the registration foundation to pursue federal opportunities aligned with those capabilities and build relationships with government customers and industry partners.”

Bimergen’s growth strategy combines battery energy storage development with technology and capital partnerships designed to advance projects toward construction and operation. Participation in the federal marketplace offers a potential additional customer channel that complements the Company’s activities across U.S. power markets and its focus on reliable, resilient energy infrastructure.

“Our strategy is to convert development capabilities and strong partnerships into long-term shareholder value,” said Bob Brilon, Co-CEO of Bimergen Energy. “Active SAM.gov registration broadens the opportunities related to hundreds of millions of government contract dollars that we can pursue as we grow our business. We see federal contracting as a potential extension of our commercial strategy, with an emphasis on opportunities that fit our capabilities and support disciplined growth.”

The registration milestone builds on Bimergen’s ongoing efforts to expand its market presence, advance its energy storage portfolio, and establish partnerships that support project execution. The Company remains focused on matching development opportunities with the technology, capital, and operational resources needed to create lasting value.

About Bimergen Energy Corporation

Bimergen Energy Corporation (NYSE American: BESS) is a U.S.-based energy infrastructure developer, asset owner, and operator focused on utility-scale and distributed battery energy storage systems (BESS). The Company develops projects designed to enhance grid reliability, support renewable energy integration, and provide flexible energy solutions across key U.S. power markets. Bimergen works with technology providers and capital partners to advance projects through development, construction, and long-term operation.

For more information about Bimergen Energy, please visit www.bimergen.com.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. These statements include expectations regarding federal contracting and assistance opportunities, potential customer and market expansion, project development, strategic partnerships, and long-term shareholder value. Forward-looking statements may be identified by words such as “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” and similar expressions.

Forward-looking statements are based on Bimergen Energy Corporation’s current expectations and assumptions. Actual results may differ materially due to factors including procurement requirements and award decisions, competition, financing availability, regulatory approvals, project execution, and other risks described in the Company’s Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this announcement. Bimergen Energy Corporation undertakes no obligation to update these statements except as required by applicable law.

Media Contact:

Dave Gentry
RedChip Companies Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447)
[email protected]



Posted on

J.P. Morgan to host its 11th India Conference in Mumbai

J.P. Morgan to host its 11th India Conference in Mumbai

MUMBAI, India–(BUSINESS WIRE)–
J.P. Morgan will kick off its eleventh India Conference on Monday, September 21, bringing together some of the world’s leading investors, business leaders, policymakers, and market participants to discuss the key themes shaping India’s next phase of growth and its role in an increasingly complex global landscape.

The two-day conference is expected to attract close to 1200 delegates representing over 100 companies and institutional investors from across the world with a collective market cap exceeding USD 1.5 trillion. The conference is J.P. Morgan’s largest-ever India conference, reflecting record levels of engagement and growing interest in India’s long term growth story.

“The India Conference demonstrates our strong belief in India’s long-term potential and our commitment to helping connect global investors with ideas, companies and policy makers shaping the country’s future,” said Sjoerd Leenart, CEO of J.P. Morgan, Asia Pacific. “India is increasingly at the centre of global growth conversations and bringing together perspectives from across business, government and the investment community has never been more important.”

Over two days, the conference will explore a wide range of themes, including India’s economic outlook, the evolving geopolitical environment, capital flows, manufacturing, consumption innovation, artificial intelligence and opportunities emerging from India’s continued economic transformation.

“Despite today’s uncertain global backdrop, India stands out for its resilience, policy stability and ability to sustain growth at scale,” said Rahul Badhwar, Senior Country Officer – India, J.P.Morgan. “The conversations taking place at this conference are ultimately about what comes next for India, where the new engines of growth will emerge, how capital will be deployed, and how businesses can position themselves for the opportunities ahead.”

About JPMorgan Chase & Co.

JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America (“U.S.”), with operations worldwide. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world’s most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.

J.P. Morgan in India

J.P. Morgan is a leading global financial services firm with physical presence in India since 1922. The firm has consistently invested in the India business, which has been growing steadily. The lines of business include Investment & Commercial Banking, Markets, Payments and Custody Services. J.P. Morgan is among the country’s leading players in almost all its businesses and primarily caters to the firm’s global clients with business interests in India and local multinationals’ growing their footprint internationally. India is home to the Corporate Center which services J.P. Morgan’s businesses around the world in the areas of operations, technology and research.

Media Contacts

Mollica Senapati: +91 22 6157 5055

Sanam Mirchandani: +91 22 6157 5091

KEYWORDS: New York United States India North America Asia Pacific

INDUSTRY KEYWORDS: Banking Other Professional Services Professional Services Finance

MEDIA:

Logo
Logo
Posted on

INV Securities Losses: Innventure Investors with Losses on their Investment are Reminded to Contact BFA Law by October 27 Deadline in Securities Fraud Class Action

Innventure has been sued for securities fraud after its stock plummeted 55% because Innventure allegedly misrepresented the strength and viability of Accelsius’ alleged DarkNX data center deal.

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Innventure, Inc. (NASDAQ:INV) and certain of the company’s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.

If you invested in Innventure, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/innventure-class-action-lawsuit.

Key Details of the Innventure ($INV) Class Action:

  • Lead Plaintiff Deadline: October 27, 2026
  • Alleged Misconduct: Securities fraud alleging Innventure misrepresented the strength and viability of Accelsius’ alleged DarkNX data center deal
  • Largest Alleged Stock Drop: August 14, 2026 – 55% Stock Drop
  • Court: U.S. District Court for the Southern District of New York
  • Action: Contact BFA Law to discuss your rights

Investors have until October 27, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Innventure securities. The class action is pending in the U.S. District Court for the Southern District of New York. It is captioned Labed v. Innventure, Inc. et al., No. 26-cv-07377.

Why is Innventure Being Sued for Securities Fraud?

Innventure is an industrial technology commercialization company. Its key subsidiary, Accelsius, develops and commercializes direct-to-chip liquid cooling technology for data centers and high-performance computing environments.

According to the complaint, Innventure repeatedly highlighted Accelsius’ agreement with DarkNX to deploy Accelsius’ NeuCool technology across a new 300MW AI data center campus in Ontario, Canada. Innventure allegedly described the deal as a major commercial milestone, projected Accelsius to be cash flow positive by year-end 2026, and used the DarkNX agreement to support expectations for substantial revenue growth.

As alleged, Defendants failed to disclose that the DarkNX deal was unlikely to materialize because there was no evidence that DarkNX was constructing or facilitating a large-scale AI data center.

Why did Innventure’s Stock Drop?

On May 28, 2026, before the market opened, Morpheus Research published a report alleging that Innventure’s DarkNX data center venture was fabricated. The report stated that there was “zero evidence” the project existed or that DarkNX had the team or funding to pursue it, and quoted former employees who questioned whether DarkNX had customers, a data center, or the ability to complete the announced project.

On this news, Innventure’s stock dropped $0.54 per share, or 8.42%, from a closing price of $6.41 per share on May 27, 2026, to $5.87 per share on May 28, 2026.

Then, on August 13, 2026, after the market closed, Innventure suspended its previously communicated 2026 revenue and cash flow targets for Accelsius, and disclosed that Accelsius had removed the DarkNX project from internal bookings because the identified deployment site was no longer available.

On this news, Innventure’s stock dropped $1.98 per share, or 55%, from a closing price of $3.60 per share on August 13, 2026, to $1.62 per share on August 14, 2026.

Click here for more information:

https://www.bfalaw.com/cases/innventure-class-action-lawsuit

.

What Can You Do?

If you invested in Innventure, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/innventure-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.”  One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/innventure-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.